EdgeMarket › What Ecor1 Capital, Llc reported owning
What Ecor1 Capital, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
2.4BPositions
30Quarter
2026-03-31Shown below
29largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ZYME Zymeworks Inc. | 575.2M | 24.4% | 23.0M | 28.67 | +100.2% |
| ANAB ANAPTYSBIO, INC | 437.0M | 18.5% | 7.9M | 57.74 | +186.6% |
| JAZZ Jazz Pharmaceuticals plc | 322.6M | 13.7% | 1.7M | 254.28 | +113.6% |
| unmapped CUSIP 152309100 | 238.3M | 10.1% | 6.0M | — | — |
| CRNX Crinetics Pharmaceuticals, Inc. | 155.7M | 6.6% | 4.3M | 84.69 | +191.1% |
| AKTS Aktis Oncology, Inc. | 86.3M | 3.7% | 4.8M | 24.07 | +19858.5% |
| ORIC Oric Pharmaceuticals, Inc. | 85.2M | 3.6% | 6.7M | 14.20 | +49.3% |
| CGON CG Oncology, Inc. | 74.6M | 3.2% | 1.1M | 79.81 | +212.6% |
| CRSP CRISPR Therapeutics AG | 66.1M | 2.8% | 1.4M | 59.50 | +12.1% |
| ETON Eton Pharmaceuticals, Inc. | 53.6M | 2.3% | 2.2M | 63.47 | +283.5% |
| LKFT Lakefront Biotherapeutics NV | 50.0M | 2.1% | 1.7M | 28.80 | -9.3% |
| XNCR Xencor Inc | 26.3M | 1.1% | 2.2M | 27.80 | +270.2% |
| NGNE Neurogene Inc. | 25.6M | 1.1% | 1.3M | 38.63 | +97.0% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 25.3M | 1.1% | 2.8M | 9.08 | -5.7% |
| MBX MBX Biosciences, Inc. | 23.2M | 1.0% | 777.0K | 66.33 | +386.6% |
| RLAY Relay Therapeutics, Inc. | 19.0M | 0.8% | 1.9M | 19.44 | +471.8% |
| ZBIO Zenas BioPharma, Inc. | 15.4M | 0.7% | 789.5K | 32.29 | +97.9% |
| ERAS Erasca, Inc. | 14.6M | 0.6% | 900.0K | 17.63 | +1107.5% |
| EIKN Eikon Therapeutics, Inc. | 7.8M | 0.3% | 732.6K | 11.39 | — |
| REPL Replimune Group, Inc. | 7.7M | 0.3% | 1.0M | 14.77 | +181.3% |
| ZURA Zura Bio Ltd | 7.0M | 0.3% | 1.2M | 5.85 | +234.3% |
| PHAT Phathom Pharmaceuticals, Inc. | 6.9M | 0.3% | 625.0K | 8.87 | -16.6% |
| MREO Mereo BioPharma Group plc | 4.4M | 0.2% | 13.4M | 0.29 | -82.2% |
| STOK Stoke Therapeutics, Inc. | 3.3M | 0.1% | 100.0K | 32.29 | +67.1% |
| PRLD Prelude Therapeutics Inc | 3.2M | 0.1% | 947.0K | 6.63 | +531.4% |
| IBIO iBio, Inc. | 3.0M | 0.1% | 1.6M | 1.43 | +88.2% |
| HLXC Helix Acquisition Corp. III | 2.0M | 0.1% | 200.0K | 10.93 | — |
| ATRA Atara Biotherapeutics, Inc. | 471.1K | 0.0% | 99.6K | 9.70 | -17.5% |
| SRZNW Surrozen, Inc./DE | 129.5K | 0.0% | 4.4K | 0.00 | -90.3% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →